Agenus cancer cocktail records 0% response rate, missing midstage goal

Agenus' Cancer Cocktail Misses Primary Goal in Phase 2 Gastroesophageal Cancer Study

Agenus and its spinout MiNK Therapeutics reported that their investigational cocktail, comprising botensilimab, balstilimab, and agenT-797, combined with Cyramza and chemotherapy, failed to meet its primary goal in a Phase 2 study for advanced gastroesophageal adenocarcinoma. The study, involving 15 eligible patients with PD-1 refractory disease, showed a 0% overall response rate (ORR). Despite this, the companies highlighted a 73% stable disease rate and promising overall survival findings, particularly in a subpopulation receiving an induction cycle, which demonstrated a median progression-free survival of 6.9 months. Safety data were consistent with component agents, with all 17 patients experiencing adverse events and 53% experiencing grade 3 or higher events.

• The investigational cocktail, consisting of Agenus' botensilimab (anti-CTLA-4 antibody) and balstilimab (PD-1 blocker), MiNK's allogeneic cell therapy agenT-797, plus Cyramza and chemotherapy, failed to achieve its primary endpoint of overall response rate (ORR) in a Phase 2 study. The efficacy analysis in 15 eligible patients with advanced, PD-1 refractory gastroesophageal adenocarcinoma showed a 0% ORR, falling short of the 28% ORR previously observed with second-line Cyramza and chemotherapy alone.
• Despite the primary endpoint miss, Agenus and MiNK highlighted encouraging secondary findings related to disease control and survival. The study reported a 73% stable disease rate among patients. Furthermore, three patients achieved overall survival exceeding 20 months, with one patient remaining progression-free for over 22 months. These durability and survival signals are considered clinically relevant by the companies, supporting continued investigation into the cocktail's potential.
• A subpopulation analysis revealed a significant benefit from an induction strategy, where patients received an initial cycle of the cocktail before concurrent therapy. This approach resulted in a median progression-free survival (PFS) of 6.9 months, compared to 3.5 months for patients who started all therapies together. The induction strategy was also associated with higher 12-month and 18-month survival rates, suggesting potential immune activation and tumor reprogramming that warrants further study.
• The safety profile of the investigational cocktail was reported as consistent with its individual component agents. All 17 patients in the study experienced at least one adverse event (AE), with 53% experiencing grade 3 or higher events. The most frequently observed treatment-emergent AEs included fatigue, fever, and diarrhea. Immune-related AEs occurred in 53% of patients, with four of these classified as grade 3 or higher.

Safety and Tolerability Profile of Botensilimab, Balstilimab, and agenT-797

Published safety and tolerability data for botensilimab and balstilimab demonstrates generally manageable adverse event profiles across multiple cancer indications, with diarrhea/colitis being the most frequently reported treatment-related adverse event. The combination has been studied in ovarian cancer, colorectal cancer, and soft tissue sarcomas, while balstilimab has also been evaluated in cervical cancer both as monotherapy and in combination with zalifrelimab.

• Ovarian cancer (botensilimab + balstilimab): In 44 treatment-refractory patients with median 3 prior therapy lines, diarrhea/colitis was the most common treatment-related adverse event (43%; 16% grade 3), with no treatment-related deaths and manageable, reversible toxicities over 9.6 months median follow-up

• Microsatellite-stable metastatic colorectal cancer (botensilimab + balstilimab): Most frequent treatment-related adverse events were fatigue and diarrhea, with a distinctly different toxicity profile compared to standard chemotherapy regimens that typically cause hematologic effects, nausea, hypertension, and dermatological toxicity

• Cervical cancer (balstilimab ± zalifrelimab): The combination produced a manageable safety profile with meaningful and durable activity in previously treated patients with persistent recurrent/metastatic disease, showing improved clinical benefit over monotherapy in phase II trials

• Soft tissue sarcomas (doxorubicin + zalifrelimab + balstilimab): Grade 3/4 treatment-related adverse events occurred in 45% of 28 evaluable patients, with immune-mediated adverse events requiring immunosuppression in 9% of cases

Note: No safety data for agenT-797 was identified in the available literature.

Beyond Gastroesophageal Adenocarcinoma: The Broader Pipeline for Agenus and MiNK

Agenus is pursuing botensilimab and balstilimab combinations across multiple tumor types beyond gastroesophageal adenocarcinoma, with particularly promising activity in immunotherapy-resistant malignancies. These trials employ diverse intervention models ranging from single-arm studies to randomized controlled designs, with most focusing on heavily pretreated patient populations.

• Advanced sarcomas (NCT03860272) - Phase I dose-escalation study with botensilimab (1-2 mg/kg IV every 6 weeks) plus balstilimab (3 mg/kg IV every 2 weeks) for up to 2 years, demonstrating 19.2% overall response rate and particularly robust activity in angiosarcoma (27.8% ORR)

• Platinum-resistant/refractory ovarian cancer - Phase 1b study using the same dosing regimen as sarcomas, achieving 23% confirmed response rate in heavily pretreated patients (median 3 prior lines) with median duration of response of 9.7 months

• Advanced/metastatic soft tissue sarcomas (NCT04028063) - Single-arm Phase 2 trial combining doxorubicin with zalifrelimab and balstilimab in checkpoint inhibitor-naïve patients, employing Simon minimax two-stage design with 46.4% progression-free survival at 6 months

• Recurrent/metastatic cervical cancer - Multiple Phase 2 studies including balstilimab monotherapy (15% ORR) and combination with zalifrelimab (25.6% ORR), with the RaPiDS study (NCT03894215) employing 1:1 randomized design comparing monotherapy versus combination

• Microsatellite-stable metastatic colorectal cancer - Phase I evaluation in heavily pretreated patients showing superior median overall survival compared to standard care (HR 0.62 versus trifluridine-tipiracil plus bevacizumab)

• Treatment-refractory glioblastoma - Clinical trial (NCT05864534) investigating combinatorial approach with anti-PD-1 and doxorubicin delivered via low-intensity pulsed ultrasound, based on preclinical data showing 90% cure rate in murine models

Refractory GEA: A Setback for Multi-Modal Immunotherapy

The landscape of advanced gastroesophageal adenocarcinoma (GEA) remains challenging, particularly for patients whose disease has progressed after prior immune checkpoint inhibitor (ICI) therapy. This patient population, often termed PD-1 refractory, represents a significant unmet medical need, with limited effective treatment options. The recent Phase 2 study evaluating a complex investigational cocktail—comprising botensilimab, balstilimab, agenT-797, Cyramza (ramucirumab), and chemotherapy—aimed to address this challenge by combining multiple mechanisms of action. However, the reported 0% overall response rate (ORR) in this study is a stark reminder of the inherent difficulties in overcoming advanced disease resistance.

Ramucirumab, an anti-VEGFR2 monoclonal antibody, holds a well-established position as a standard second-line treatment for advanced gastric/GEJ adenocarcinoma, demonstrating improvements in overall survival and progression-free survival when used alone or with paclitaxel. Its inclusion in this cocktail was likely intended to leverage its anti-angiogenic properties alongside the immunomodulatory effects of the other agents. The failure to achieve any objective responses with this multi-modal approach in PD-1 refractory patients suggests that simply layering therapies, even those with individual efficacy, may not translate into synergistic benefit in such a resistant setting. This outcome prompts a critical re-evaluation of combination strategies, particularly the optimal selection and sequencing of agents to overcome complex resistance mechanisms.

• Strategic Reassessment: Companies developing multi-modal therapies for refractory cancers must carefully reassess the rationale for combining numerous agents, especially when targeting patient populations with demonstrated resistance to key components. The complexity of such regimens often comes with increased toxicity, as evidenced by the 53% incidence of Grade 3 or higher adverse events in this study.

• Biomarker-Driven Development: While the 0% ORR is a significant setback, the reported 73% stable disease rate and "promising overall survival findings" in a subpopulation hint at potential biological activity. This underscores the critical need for robust biomarker identification to pinpoint patient subsets most likely to benefit from specific components or refined versions of the cocktail. Future development efforts should prioritize precision medicine approaches to avoid exposing non-responders to unnecessary toxicity.

• Ramucirumab's Enduring Role: The study's outcome does not diminish ramucirumab's established efficacy in its approved indications. Its role as a second-line standard in advanced gastric/GEJ adenocarcinoma, often in combination with paclitaxel, remains a cornerstone of treatment. The challenge lies in integrating it effectively into novel, highly complex regimens for patients who have exhausted other options.

Ultimately, this Phase 2 result highlights the ongoing quest for effective therapies in advanced GEA, particularly for those who have progressed on immunotherapy. It reinforces the need for innovative, yet carefully validated, strategies that balance efficacy with manageable toxicity, guided by a deeper understanding of tumor biology and patient-specific factors.